PURPOSE OF REVIEW: The review provides updates on novel risk markers for the development of pediatric inflammatory uveitis and a severe disease course, on treatment of refractory disease, and on the measurement of visual outcomes. RECENT FINDINGS: There are several new genetic markers, biomarkers, and clinical factors that may influence a child's uveitis disease course. It is important to identify children at risk for poor visual outcomes and who are refractory to traditional therapy. Racial disparities have recently been reported. We describe agents of potential benefit. In addition, we discuss the importance of patient reported outcomes in this population. SUMMARY: Uveitis can lead to vision-threatening complications. Timely and aggressive treatment of children identified to be at risk for a severe uveitis course may lead to improved outcomes.
PURPOSE OF REVIEW: The review provides updates on novel risk markers for the development of pediatric inflammatory uveitis and a severe disease course, on treatment of refractory disease, and on the measurement of visual outcomes. RECENT FINDINGS: There are several new genetic markers, biomarkers, and clinical factors that may influence a child's uveitis disease course. It is important to identify children at risk for poor visual outcomes and who are refractory to traditional therapy. Racial disparities have recently been reported. We describe agents of potential benefit. In addition, we discuss the importance of patient reported outcomes in this population. SUMMARY:Uveitis can lead to vision-threatening complications. Timely and aggressive treatment of children identified to be at risk for a severe uveitis course may lead to improved outcomes.
Authors: Grace Levy-Clarke; Douglas A Jabs; Russell W Read; James T Rosenbaum; Albert Vitale; Russell N Van Gelder Journal: Ophthalmology Date: 2013-12-17 Impact factor: 12.079
Authors: Arenda J W Haasnoot; Maretta van Tent-Hoeve; Nico M Wulffraat; Nicoline E Schalij-Delfos; Leonoor I Los; Wineke Armbrust; Nicolaas P A Zuithoff; Joke H de Boer Journal: Am J Ophthalmol Date: 2014-11-07 Impact factor: 5.258
Authors: Viera Kalinina Ayuso; Evelyne Leonce van de Winkel; Aniki Rothova; Joke Helena de Boer Journal: Am J Ophthalmol Date: 2010-12-09 Impact factor: 5.258
Authors: Sheila T Angeles-Han; Courtney McCracken; Steven Yeh; Kirsten Jenkins; Daneka Stryker; Curtis Travers; Kelly Rouster-Stevens; Larry B Vogler; Scott R Lambert; Carolyn Drews-Botsch; Sampath Prahalad Journal: Am J Ophthalmol Date: 2015-08-06 Impact factor: 5.258
Authors: Viera Kalinina Ayuso; Joke H de Boer; Helen L Byers; Gary R Coulton; Jojanneke Dekkers; Lenneke de Visser; Anton M van Loon; Peter A W J F Schellekens; Aniki Rothova; Jolanda D F de Groot-Mijnes Journal: Invest Ophthalmol Vis Sci Date: 2013-05-01 Impact factor: 4.799
Authors: Waleed A Hassan; Basma M Medhat; Maha M Youssef; Yomna Farag; Noha Mostafa; Alshaimaa R Alnaggar; Mervat E Behiry; Rasha A Abdel Noor; Riham S H M Allam Journal: Clin Rheumatol Date: 2020-09-02 Impact factor: 2.980